Amicus Brief Seeks to Provide Relief From Aetna’s ‘Level of Severity’ Policy

Why It Matters

The outcome could reshape payer‑hospital contracts by limiting insurers’ ability to unilaterally alter reimbursement structures, preserving hospital revenue stability and patient transparency.

Key Takeaways

• AHA files amicus brief to block Aetna’s severity‑based reimbursement.
• Policy treats low‑severity inpatient stays like observation, lowering payments.
• Hospitals face financial hits and added administrative workload from mid‑contract changes.
• AHA argues policy erodes consumer transparency and undermines coverage protections.
• Potential court relief could force Aetna to rescind or modify policy.

Pulse Analysis

Aetna’s new “level of severity” policy, rolled out in January, reclassifies certain low‑severity inpatient admissions as comparable to observation status. By tying reimbursement to a severity metric rather than traditional DRG rates, the insurer effectively reduces payment levels for stays that would previously have commanded higher inpatient rates. This shift mirrors a broader industry push to contain costs, but it also blurs the line between inpatient and observation care, creating uncertainty for hospitals that must now justify higher resource use with lower payments.

The American Hospital Association’s amicus brief, filed June 5 in the Eastern District of Pennsylvania, seeks declaratory or injunctive relief to halt the policy’s enforcement. By positioning the issue as both a financial threat and an administrative burden, the AHA underscores how mid‑contract policy changes can destabilize hospital revenue cycles and inflate staffing costs for billing compliance. The brief also highlights potential violations of consumer‑protection statutes, arguing that patients lose transparency when insurers retroactively alter coverage definitions. A favorable ruling could set precedent for challenging similar severity‑based models nationwide.

If the court grants relief, Aetna may be compelled to rescind the severity tier or renegotiate rates, restoring traditional inpatient payments for low‑severity cases. Such an outcome would reinforce hospitals’ bargaining power and could prompt other payers to reconsider aggressive cost‑shifting tactics. Conversely, a dismissal would embolden insurers to expand severity‑based pricing, accelerating a shift toward observation‑style reimbursement across the acute‑care landscape. Stakeholders should monitor the case as an early indicator of how regulatory scrutiny and litigation will shape payer‑hospital contracts in the coming years.